Non-Hodgkin Lymphoma – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Non-Hodgkin Lymphoma – Pipeline Review, H2 2016’, provides an overview of the Non-Hodgkin Lymphoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Non-Hodgkin Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non-Hodgkin Lymphoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Non-Hodgkin Lymphoma

The report reviews pipeline therapeutics for Non-Hodgkin Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Non-Hodgkin Lymphoma therapeutics and enlists all their major and minor projects

The report assesses Non-Hodgkin Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Non-Hodgkin Lymphoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Non-Hodgkin Lymphoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

4SC AG

AB Science SA

AbbVie Inc

Acetylon Pharmaceuticals Inc

Actelion Ltd

Actinium Pharmaceuticals Inc

ADC Therapeutics Sarl

Affimed GmbH

Allinky Biopharma

Altor BioScience Corp

Amgen Inc

Angimmune LLC

arGEN-X BV

Arno Therapeutics Inc

Arrien Pharmaceuticals LLC

Arvinas Inc

Asana BioSciences LLC

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Atara Biotherapeutics Inc

Aurigene Discovery Technologies Ltd

Bayer AG

BeiGene Ltd

Bellicum Pharmaceuticals Inc

Bio-Path Holdings Inc

BioAtla LLC

Biocon Ltd

Biogen Inc

Biogenomics Ltd

BioInvent International AB

BioLineRx Ltd

Bionovis SA

BioNTech AG

BioSight Ltd

Biothera Pharmaceutical Inc

bluebird bio Inc

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Company

Calimmune Inc

Calithera Biosciences Inc

Celgene Corp

Cell Medica Ltd

Cell Source Inc

Cell>Point LLC

Celldex Therapeutics Inc

Cellectar Biosciences Inc

Cellectis SA

Celltrion Inc

Cellular Biomedicine Group Inc

Celon Pharma Sp z oo

CerRx Inc

Chipscreen Biosciences Ltd

Clevexel Pharma SA

Coherus BioSciences Inc

Constellation Pharmaceuticals Inc

Cornerstone Pharmaceuticals Inc

CrystalGenomics Inc

CSPC Pharmaceutical Group Limited

CTI BioPharma Corp

Curis Inc

Cyclacel Pharmaceuticals Inc

Daiichi Sankyo Company Ltd

Dynavax Technologies Corp

eFFECTOR Therapeutics Inc

Eisai Co Ltd

Eli Lilly and Company

EpiZyme Inc

Erytech Pharma SA

Evotec AG

F. Hoffmann-La Roche Ltd

Formula Pharmaceuticals Inc

Galderma SA

Gamida Cell Ltd

Genentech Inc

Genor BioPharma Co Ltd

Genosco

Gilead Sciences Inc

GlaxoSmithKline Plc

Grupo Ferrer Internacional SA

H3 Biomedicine Inc

Humorigin Biotechnology Corp

Hutchison MediPharma Ltd

iDD biotech SAS

IGF Oncology LLC

Ignyta Inc

Immune Design Corp

ImmunoGen Inc

Immunomedics Inc

Immunovaccine Inc

Incyte Corp

Inflection Biosciences Ltd

Innate Pharma SA

Innovent Biologics Inc

Japan Tobacco Inc

JHL Biotech Inc

Johnson & Johnson

Juno Therapeutics Inc

Kainos Medicine Inc

Karyopharm Therapeutics Inc

Kite Pharma Inc

Komipharm International Co Ltd

Kyowa Hakko Kirin Co Ltd

LFB SA

Mabion SA

mAbxience SA

MacroGenics Inc

MedImmune LLC

Medivation Inc

MEI Pharma Inc

Merck & Co Inc

Merck KGaA

Mesoblast Ltd

Millennium Pharmaceuticals Inc

miRagen Therapeutics Inc

Mirati Therapeutics Inc

Molecular Templates Inc

Moleculin Biotech Inc

Molplex Ltd

MorphoSys AG

Mundipharma International Ltd

NantKwest Inc

Neumedicines Inc

Nimbus Therapeutics LLC

Nordic Nanovector ASA

NovaLead Pharma Pvt Ltd

Novartis AG

NovImmune SA

Oncobiologics Inc

Onconova Therapeutics Inc

OncoSec Medical Inc

Oncternal Therapeutics Inc

Ono Pharmaceutical Co Ltd

Onxeo SA

Oxford BioTherapeutics Ltd

OXIS International, Inc.

Panacea Biotec Ltd

Patrys Ltd

Pfizer Inc

Pharma Mar SA

Pharmacyclics Inc

Philogen SpA

Polaris Pharmaceuticals Inc

Portola Pharmaceuticals Inc

RedHill Biopharma Ltd

Regeneron Pharmaceuticals Inc

Respiratorius AB

Rhizen Pharmaceuticals SA

Richter Gedeon Nyrt

Sandoz International GmbH

Sanofi

Sareum Holdings Plc

SciTech Development LLC

Seattle Genetics Inc

Selvita SA

Senhwa Biosciences Inc

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Shanghai Henlius Biotech Co Ltd

Shanghai Pharmaceutical Co Ltd

SialoTec GmbH

Sigma-Tau SpA

Simcere Pharmaceutical Group

Solasia Pharma KK

Soligenix Inc

Sorrento Therapeutics Inc

Spectrum Pharmaceuticals Inc

Stemline Therapeutics Inc

Supratek Pharma Inc

Sutro Biopharma Inc

Taiho Pharmaceutical Co Ltd

Taiwan Liposome Company Ltd

Takara Bio Inc

Takeda Pharmaceutical Company Ltd

Targazyme Inc

TetraLogic Pharmaceuticals

Teva Pharmaceutical Industries Ltd

TG Therapeutics Inc

The International Biotechnology Center (IBC) Generium

Theravectys SA

TRACON Pharmaceuticals Inc

Transgene Biotek Ltd

Transgene SA

Trillium Therapeutics Inc

United BioPharma Inc

Unum Therapeutics Inc

Verastem Inc

Vivolux AB

Xencor Inc

Xenetic Biosciences (UK) Ltd

ZIOPHARM Oncology Inc

Zymeworks Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 11

Non-Hodgkin Lymphoma Overview 12

Therapeutics Development 13

Non-Hodgkin Lymphoma - Therapeutics under Development by Companies 15

Non-Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes 32

Non-Hodgkin Lymphoma - Pipeline Products Glance 34

Non-Hodgkin Lymphoma - Products under Development by Companies 38

Non-Hodgkin Lymphoma - Products under Investigation by Universities/Institutes 88

Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development 92

Non-Hodgkin Lymphoma - Therapeutics Assessment 287

Drug Profiles 354

Non-Hodgkin Lymphoma - Dormant Projects 1528

Non-Hodgkin Lymphoma - Discontinued Products 1561

Non-Hodgkin Lymphoma - Product Development Milestones 1574

Appendix 1584

List of Tables

List of Tables

Number of Products under Development for Non-Hodgkin Lymphoma, H2 2016 58

Number of Products under Development for Non-Hodgkin Lymphoma – Comparative Analysis, H2 2016 59

Number of Products under Development by Companies, H2 2016 61

Number of Products under Development by Companies, H2 2016 (Contd..1) 62

Number of Products under Development by Companies, H2 2016 (Contd..2) 63

Number of Products under Development by Companies, H2 2016 (Contd..3) 64

Number of Products under Development by Companies, H2 2016 (Contd..4) 65

Number of Products under Development by Companies, H2 2016 (Contd..5) 66

Number of Products under Development by Companies, H2 2016 (Contd..6) 67

Number of Products under Development by Companies, H2 2016 (Contd..7) 68

Number of Products under Development by Companies, H2 2016 (Contd..8) 69

Number of Products under Development by Companies, H2 2016 (Contd..9) 70

Number of Products under Development by Companies, H2 2016 (Contd..10) 71

Number of Products under Development by Companies, H2 2016 (Contd..11) 72

Number of Products under Development by Companies, H2 2016 (Contd..12) 73

Number of Products under Development by Companies, H2 2016 (Contd..13) 74

Number of Products under Development by Companies, H2 2016 (Contd..14) 75

Number of Products under Development by Companies, H2 2016 (Contd..15) 76

Number of Products under Investigation by Universities/Institutes, H2 2016 77

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 78

Comparative Analysis by Late Stage Development, H2 2016 79

Comparative Analysis by Clinical Stage Development, H2 2016 80

Comparative Analysis by Early Stage Development, H2 2016 81

Comparative Analysis by Unknown Stage Development, H2 2016 82

Products under Development by Companies, H2 2016 83

Products under Development by Companies, H2 2016 (Contd..1) 84

Products under Development by Companies, H2 2016 (Contd..2) 85

Products under Development by Companies, H2 2016 (Contd..3) 86

Products under Development by Companies, H2 2016 (Contd..4) 87

Products under Development by Companies, H2 2016 (Contd..5) 88

Products under Development by Companies, H2 2016 (Contd..6) 89

Products under Development by Companies, H2 2016 (Contd..7) 90

Products under Development by Companies, H2 2016 (Contd..8) 91

Products under Development by Companies, H2 2016 (Contd..9) 92

Products under Development by Companies, H2 2016 (Contd..10) 93

Products under Development by Companies, H2 2016 (Contd..11) 94

Products under Development by Companies, H2 2016 (Contd..12) 95

Products under Development by Companies, H2 2016 (Contd..13) 96

Products under Development by Companies, H2 2016 (Contd..14) 97

Products under Development by Companies, H2 2016 (Contd..15) 98

Products under Development by Companies, H2 2016 (Contd..16) 99

Products under Development by Companies, H2 2016 (Contd..17) 100

Products under Development by Companies, H2 2016 (Contd..18) 101

Products under Development by Companies, H2 2016 (Contd..19) 102

Products under Development by Companies, H2 2016 (Contd..20) 103

Products under Development by Companies, H2 2016 (Contd..21) 104

Products under Development by Companies, H2 2016 (Contd..22) 105

Products under Development by Companies, H2 2016 (Contd..23) 106

Products under Development by Companies, H2 2016 (Contd..24) 107

Products under Development by Companies, H2 2016 (Contd..25) 108

Products under Development by Companies, H2 2016 (Contd..26) 109

Products under Development by Companies, H2 2016 (Contd..27) 110

Products under Development by Companies, H2 2016 (Contd..28) 111

Products under Development by Companies, H2 2016 (Contd..29) 112

Products under Development by Companies, H2 2016 (Contd..30) 113

Products under Development by Companies, H2 2016 (Contd..31) 114

Products under Development by Companies, H2 2016 (Contd..32) 115

Products under Development by Companies, H2 2016 (Contd..33) 116

Products under Development by Companies, H2 2016 (Contd..34) 117

Products under Development by Companies, H2 2016 (Contd..35) 118

Products under Development by Companies, H2 2016 (Contd..36) 119

Products under Development by Companies, H2 2016 (Contd..37) 120

Products under Development by Companies, H2 2016 (Contd..38) 121

Products under Development by Companies, H2 2016 (Contd..39) 122

Products under Development by Companies, H2 2016 (Contd..40) 123

Products under Development by Companies, H2 2016 (Contd..41) 124

Products under Development by Companies, H2 2016 (Contd..42) 125

Products under Development by Companies, H2 2016 (Contd..43) 126

Products under Development by Companies, H2 2016 (Contd..44) 127

Products under Development by Companies, H2 2016 (Contd..45) 128

Products under Development by Companies, H2 2016 (Contd..46) 129

Products under Development by Companies, H2 2016 (Contd..47) 130

Products under Development by Companies, H2 2016 (Contd..48) 131

Products under Development by Companies, H2 2016 (Contd..49) 132

Products under Investigation by Universities/Institutes, H2 2016 133

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 134

Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 135

Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 136

Non-Hodgkin Lymphoma – Pipeline by 3SBio Inc, H2 2016 137

Non-Hodgkin Lymphoma – Pipeline by 4SC AG, H2 2016 138

Non-Hodgkin Lymphoma – Pipeline by AB Science SA, H2 2016 139

Non-Hodgkin Lymphoma – Pipeline by AbbVie Inc, H2 2016 140

Non-Hodgkin Lymphoma – Pipeline by Acetylon Pharmaceuticals Inc, H2 2016 141

Non-Hodgkin Lymphoma – Pipeline by Actelion Ltd, H2 2016 142

Non-Hodgkin Lymphoma – Pipeline by Actinium Pharmaceuticals Inc, H2 2016 143

Non-Hodgkin Lymphoma – Pipeline by ADC Therapeutics Sarl, H2 2016 144

Non-Hodgkin Lymphoma – Pipeline by Affimed GmbH, H2 2016 145

Non-Hodgkin Lymphoma – Pipeline by Allinky Biopharma, H2 2016 146

Non-Hodgkin Lymphoma – Pipeline by Altor BioScience Corp, H2 2016 147

Non-Hodgkin Lymphoma – Pipeline by Amgen Inc, H2 2016 148

Non-Hodgkin Lymphoma – Pipeline by Angimmune LLC, H2 2016 149

Non-Hodgkin Lymphoma – Pipeline by arGEN-X BV, H2 2016 150

Non-Hodgkin Lymphoma – Pipeline by Arno Therapeutics Inc, H2 2016 151

Non-Hodgkin Lymphoma – Pipeline by Arrien Pharmaceuticals LLC, H2 2016 152

Non-Hodgkin Lymphoma – Pipeline by Arvinas Inc, H2 2016 153

Non-Hodgkin Lymphoma – Pipeline by Asana BioSciences LLC, H2 2016 154

Non-Hodgkin Lymphoma – Pipeline by Astellas Pharma Inc, H2 2016 155

Non-Hodgkin Lymphoma – Pipeline by Astex Pharmaceuticals Inc, H2 2016 156

Non-Hodgkin Lymphoma – Pipeline by AstraZeneca Plc, H2 2016 157

Non-Hodgkin Lymphoma – Pipeline by Atara Biotherapeutics Inc, H2 2016 158

Non-Hodgkin Lymphoma – Pipeline by Aurigene Discovery Technologies Ltd, H2 2016 159

Non-Hodgkin Lymphoma – Pipeline by Bayer AG, H2 2016 160

Non-Hodgkin Lymphoma – Pipeline by BeiGene Ltd, H2 2016 161

Non-Hodgkin Lymphoma – Pipeline by Bellicum Pharmaceuticals Inc, H2 2016 162

Non-Hodgkin Lymphoma – Pipeline by Bio-Path Holdings Inc, H2 2016 163

Non-Hodgkin Lymphoma – Pipeline by BioAtla LLC, H2 2016 164

Non-Hodgkin Lymphoma – Pipeline by Biocon Ltd, H2 2016 165

Non-Hodgkin Lymphoma – Pipeline by Biogen Inc, H2 2016 166

Non-Hodgkin Lymphoma – Pipeline by Biogenomics Ltd, H2 2016 167

Non-Hodgkin Lymphoma – Pipeline by BioInvent International AB, H2 2016 168

Non-Hodgkin Lymphoma – Pipeline by BioLineRx Ltd, H2 2016 169

Non-Hodgkin Lymphoma – Pipeline by Bionovis SA, H2 2016 170

Non-Hodgkin Lymphoma – Pipeline by BioNTech AG, H2 2016 171

Non-Hodgkin Lymphoma – Pipeline by BioSight Ltd, H2 2016 172

Non-Hodgkin Lymphoma – Pipeline by Biothera Pharmaceutical Inc, H2 2016 173

Non-Hodgkin Lymphoma – Pipeline by bluebird bio Inc, H2 2016 174

Non-Hodgkin Lymphoma – Pipeline by Boehringer Ingelheim GmbH, H2 2016 175

Non-Hodgkin Lymphoma – Pipeline by Boston Biomedical Inc, H2 2016 176

Non-Hodgkin Lymphoma – Pipeline by Bristol-Myers Squibb Company, H2 2016 177

Non-Hodgkin Lymphoma – Pipeline by Calimmune Inc, H2 2016 178

Non-Hodgkin Lymphoma – Pipeline by Calithera Biosciences Inc, H2 2016 179

Non-Hodgkin Lymphoma – Pipeline by Celgene Corp, H2 2016 180

Non-Hodgkin Lymphoma – Pipeline by Cell Medica Ltd, H2 2016 182

Non-Hodgkin Lymphoma – Pipeline by Cell Source Inc, H2 2016 183

Non-Hodgkin Lymphoma – Pipeline by Cell>Point LLC, H2 2016 184

Non-Hodgkin Lymphoma – Pipeline by Celldex Therapeutics Inc, H2 2016 185

Non-Hodgkin Lymphoma – Pipeline by Cellectar Biosciences Inc, H2 2016 186

Non-Hodgkin Lymphoma – Pipeline by Cellectis SA, H2 2016 187

Non-Hodgkin Lymphoma – Pipeline by Celltrion Inc, H2 2016 188

Non-Hodgkin Lymphoma – Pipeline by Cellular Biomedicine Group Inc, H2 2016 189

Non-Hodgkin Lymphoma – Pipeline by Celon Pharma Sp z oo, H2 2016 190

Non-Hodgkin Lymphoma – Pipeline by CerRx Inc, H2 2016 191

Non-Hodgkin Lymphoma – Pipeline by Chipscreen Biosciences Ltd, H2 2016 192

Non-Hodgkin Lymphoma – Pipeline by Clevexel Pharma SA, H2 2016 193

Non-Hodgkin Lymphoma – Pipeline by Coherus BioSciences Inc, H2 2016 194

Non-Hodgkin Lymphoma – Pipeline by Constellation Pharmaceuticals Inc, H2 2016 195

Non-Hodgkin Lymphoma – Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016 196

Non-Hodgkin Lymphoma – Pipeline by CrystalGenomics Inc, H2 2016 197

Non-Hodgkin Lymphoma – Pipeline by CSPC Pharmaceutical Group Limited, H2 2016 198

Non-Hodgkin Lymphoma – Pipeline by CTI BioPharma Corp, H2 2016 199

Non-Hodgkin Lymphoma – Pipeline by Curis Inc, H2 2016 200

Non-Hodgkin Lymphoma – Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016 201

Non-Hodgkin Lymphoma – Pipeline by Daiichi Sankyo Company Ltd, H2 2016 202

Non-Hodgkin Lymphoma – Pipeline by Dynavax Technologies Corp, H2 2016 203

Non-Hodgkin Lymphoma – Pipeline by eFFECTOR Therapeutics Inc, H2 2016 204

Non-Hodgkin Lymphoma – Pipeline by Eisai Co Ltd, H2 2016 205

Non-Hodgkin Lymphoma – Pipeline by Eli Lilly and Company, H2 2016 206

Non-Hodgkin Lymphoma – Pipeline by EpiZyme Inc, H2 2016 207

Non-Hodgkin Lymphoma – Pipeline by Erytech Pharma SA, H2 2016 208

Non-Hodgkin Lymphoma – Pipeline by Evotec AG, H2 2016 209

Non-Hodgkin Lymphoma – Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 210

Non-Hodgkin Lymphoma – Pipeline by Formula Pharmaceuticals Inc, H2 2016 211

Non-Hodgkin Lymphoma – Pipeline by Galderma SA, H2 2016 212

Non-Hodgkin Lymphoma – Pipeline by Gamida Cell Ltd, H2 2016 213

Non-Hodgkin Lymphoma – Pipeline by Genentech Inc, H2 2016 214

Non-Hodgkin Lymphoma – Pipeline by Genor BioPharma Co Ltd, H2 2016 215

Non-Hodgkin Lymphoma – Pipeline by Genosco, H2 2016 216

Non-Hodgkin Lymphoma – Pipeline by Gilead Sciences Inc, H2 2016 217

Non-Hodgkin Lymphoma – Pipeline by GlaxoSmithKline Plc, H2 2016 218

Non-Hodgkin Lymphoma – Pipeline by Grupo Ferrer Internacional SA, H2 2016 219

Non-Hodgkin Lymphoma – Pipeline by H3 Biomedicine Inc, H2 2016 220

Non-Hodgkin Lymphoma – Pipeline by Humorigin Biotechnology Corp, H2 2016 221

Non-Hodgkin Lymphoma – Pipeline by Hutchison MediPharma Ltd, H2 2016 222

Non-Hodgkin Lymphoma – Pipeline by iDD biotech SAS, H2 2016 223

Non-Hodgkin Lymphoma – Pipeline by IGF Oncology LLC, H2 2016 224

Non-Hodgkin Lymphoma – Pipeline by Ignyta Inc, H2 2016 225

Non-Hodgkin Lymphoma – Pipeline by Immune Design Corp, H2 2016 226

Non-Hodgkin Lymphoma – Pipeline by ImmunoGen Inc, H2 2016 227

Non-Hodgkin Lymphoma – Pipeline by Immunomedics Inc, H2 2016 228

Non-Hodgkin Lymphoma – Pipeline by Immunovaccine Inc, H2 2016 229

Non-Hodgkin Lymphoma – Pipeline by Incyte Corp, H2 2016 230

Non-Hodgkin Lymphoma – Pipeline by Inflection Biosciences Ltd, H2 2016 231

Non-Hodgkin Lymphoma – Pipeline by Innate Pharma SA, H2 2016 232

Non-Hodgkin Lymphoma – Pipeline by Innovent Biologics Inc, H2 2016 233

Non-Hodgkin Lymphoma – Pipeline by Japan Tobacco Inc, H2 2016 234

Non-Hodgkin Lymphoma – Pipeline by JHL Biotech Inc, H2 2016 235

Non-Hodgkin Lymphoma – Pipeline by Johnson & Johnson, H2 2016 236

Non-Hodgkin Lymphoma – Pipeline by Juno Therapeutics Inc, H2 2016 237

Non-Hodgkin Lymphoma – Pipeline by Kainos Medicine Inc, H2 2016 238

Non-Hodgkin Lymphoma – Pipeline by Karyopharm Therapeutics Inc, H2 2016 239

Non-Hodgkin Lymphoma – Pipeline by Kite Pharma Inc, H2 2016 240

Non-Hodgkin Lymphoma – Pipeline by Komipharm International Co Ltd, H2 2016 241

Non-Hodgkin Lymphoma – Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2016 242

Non-Hodgkin Lymphoma – Pipeline by LFB SA, H2 2016 243

Non-Hodgkin Lymphoma – Pipeline by Mabion SA, H2 2016 244

Non-Hodgkin Lymphoma – Pipeline by mAbxience SA, H2 2016 245

Non-Hodgkin Lymphoma – Pipeline by MacroGenics Inc, H2 2016 246

Non-Hodgkin Lymphoma – Pipeline by MedImmune LLC, H2 2016 247

Non-Hodgkin Lymphoma – Pipeline by Medivation Inc, H2 2016 248

Non-Hodgkin Lymphoma – Pipeline by MEI Pharma Inc, H2 2016 249

Non-Hodgkin Lymphoma – Pipeline by Merck & Co Inc, H2 2016 250

Non-Hodgkin Lymphoma – Pipeline by Merck KGaA, H2 2016 251

Non-Hodgkin Lymphoma – Pipeline by Mesoblast Ltd, H2 2016 252

Non-Hodgkin Lymphoma – Pipeline by Millennium Pharmaceuticals Inc, H2 2016 253

Non-Hodgkin Lymphoma – Pipeline by miRagen Therapeutics Inc, H2 2016 254

Non-Hodgkin Lymphoma – Pipeline by Mirati Therapeutics Inc, H2 2016 255

Non-Hodgkin Lymphoma – Pipeline by Molecular Templates Inc, H2 2016 256

Non-Hodgkin Lymphoma – Pipeline by Moleculin Biotech Inc, H2 2016 257

Non-Hodgkin Lymphoma – Pipeline by Molplex Ltd, H2 2016 258

Non-Hodgkin Lymphoma – Pipeline by MorphoSys AG, H2 2016 259

Non-Hodgkin Lymphoma – Pipeline by Mundipharma International Ltd, H2 2016 260

Non-Hodgkin Lymphoma – Pipeline by NantKwest Inc, H2 2016 261

Non-Hodgkin Lymphoma – Pipeline by Neumedicines Inc, H2 2016 262

Non-Hodgkin Lymphoma – Pipeline by Nimbus Therapeutics LLC, H2 2016 263

Non-Hodgkin Lymphoma – Pipeline by Nordic Nanovector ASA, H2 2016 264

Non-Hodgkin Lymphoma – Pipeline by NovaLead Pharma Pvt Ltd, H2 2016 265

Non-Hodgkin Lymphoma – Pipeline by Novartis AG, H2 2016 266

Non-Hodgkin Lymphoma – Pipeline by NovImmune SA, H2 2016 267

Non-Hodgkin Lymphoma – Pipeline by Oncobiologics Inc, H2 2016 268

Non-Hodgkin Lymphoma – Pipeline by Onconova Therapeutics Inc, H2 2016 269

Non-Hodgkin Lymphoma – Pipeline by OncoSec Medical Inc, H2 2016 270

Non-Hodgkin Lymphoma – Pipeline by Oncternal Therapeutics Inc, H2 2016 271

Non-Hodgkin Lymphoma – Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 272

Non-Hodgkin Lymphoma – Pipeline by Onxeo SA, H2 2016 273

Non-Hodgkin Lymphoma – Pipeline by Oxford BioTherapeutics Ltd, H2 2016 274

Non-Hodgkin Lymphoma – Pipeline by OXIS International, Inc., H2 2016 275

Non-Hodgkin Lymphoma – Pipeline by Panacea Biotec Ltd, H2 2016 276

Non-Hodgkin Lymphoma – Pipeline by Patrys Ltd, H2 2016 277

Non-Hodgkin Lymphoma – Pipeline by Pfizer Inc, H2 2016 278

Non-Hodgkin Lymphoma – Pipeline by Pharma Mar SA, H2 2016 279

Non-Hodgkin Lymphoma – Pipeline by Pharmacyclics Inc, H2 2016 280

Non-Hodgkin Lymphoma – Pipeline by Philogen SpA, H2 2016 281

Non-Hodgkin Lymphoma – Pipeline by Polaris Pharmaceuticals Inc, H2 2016 282

Non-Hodgkin Lymphoma – Pipeline by Portola Pharmaceuticals Inc, H2 2016 283

Non-Hodgkin Lymphoma – Pipeline by RedHill Biopharma Ltd, H2 2016 284

Non-Hodgkin Lymphoma – Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 285

Non-Hodgkin Lymphoma – Pipeline by Respiratorius AB, H2 2016 286

Non-Hodgkin Lymphoma – Pipeline by Rhizen Pharmaceuticals SA, H2 2016 287

Non-Hodgkin Lymphoma – Pipeline by Richter Gedeon Nyrt, H2 2016 288

Non-Hodgkin Lymphoma – Pipeline by Sandoz International GmbH, H2 2016 289

Non-Hodgkin Lymphoma – Pipeline by Sanofi, H2 2016 290

Non-Hodgkin Lymphoma – Pipeline by Sareum Holdings Plc, H2 2016 291

Non-Hodgkin Lymphoma – Pipeline by SciTech Development LLC, H2 2016 292

Non-Hodgkin Lymphoma – Pipeline by Seattle Genetics Inc, H2 2016 293

Non-Hodgkin Lymphoma – Pipeline by Selvita SA, H2 2016 295

Non-Hodgkin Lymphoma – Pipeline by Senhwa Biosciences Inc, H2 2016 296

Non-Hodgkin Lymphoma – Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H2 2016 297

Non-Hodgkin Lymphoma – Pipeline by Shanghai Henlius Biotech Co Ltd, H2 2016 298

Non-Hodgkin Lymphoma – Pipeline by Shanghai Pharmaceutical Co Ltd, H2 2016 299

Non-Hodgkin Lymphoma – Pipeline by SialoTec GmbH, H2 2016 300

Non-Hodgkin Lymphoma – Pipeline by Sigma-Tau SpA, H2 2016 301

Non-Hodgkin Lymphoma – Pipeline by Simcere Pharmaceutical Group, H2 2016 302

Non-Hodgkin Lymphoma – Pipeline by Solasia Pharma KK, H2 2016 303

Non-Hodgkin Lymphoma – Pipeline by Soligenix Inc, H2 2016 304

Non-Hodgkin Lymphoma – Pipeline by Sorrento Therapeutics Inc, H2 2016 305

Non-Hodgkin Lymphoma – Pipeline by Spectrum Pharmaceuticals Inc, H2 2016 306

Non-Hodgkin Lymphoma – Pipeline by Stemline Therapeutics Inc, H2 2016 307

Non-Hodgkin Lymphoma – Pipeline by Supratek Pharma Inc, H2 2016 308

Non-Hodgkin Lymphoma – Pipeline by Sutro Biopharma Inc, H2 2016 309

Non-Hodgkin Lymphoma – Pipeline by Taiho Pharmaceutical Co Ltd, H2 2016 310

Non-Hodgkin Lymphoma – Pipeline by Taiwan Liposome Company Ltd, H2 2016 311

Non-Hodgkin Lymphoma – Pipeline by Takara Bio Inc, H2 2016 312

Non-Hodgkin Lymphoma – Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 313

Non-Hodgkin Lymphoma – Pipeline by Targazyme Inc, H2 2016 314

Non-Hodgkin Lymphoma – Pipeline by TetraLogic Pharmaceuticals, H2 2016 315

Non-Hodgkin Lymphoma – Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 316

Non-Hodgkin Lymphoma – Pipeline by TG Therapeutics Inc, H2 2016 317

Non-Hodgkin Lymphoma – Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016 318

Non-Hodgkin Lymphoma – Pipeline by Theravectys SA, H2 2016 319

Non-Hodgkin Lymphoma – Pipeline by TRACON Pharmaceuticals Inc, H2 2016 320

Non-Hodgkin Lymphoma – Pipeline by Transgene Biotek Ltd, H2 2016 321

Non-Hodgkin Lymphoma – Pipeline by Transgene SA, H2 2016 322

Non-Hodgkin Lymphoma – Pipeline by Trillium Therapeutics Inc, H2 2016 323

Non-Hodgkin Lymphoma – Pipeline by United BioPharma Inc, H2 2016 324

Non-Hodgkin Lymphoma – Pipeline by Unum Therapeutics Inc, H2 2016 325

Non-Hodgkin Lymphoma – Pipeline by Verastem Inc, H2 2016 326

Non-Hodgkin Lymphoma – Pipeline by Vivolux AB, H2 2016 327

Non-Hodgkin Lymphoma – Pipeline by Xencor Inc, H2 2016 328

Non-Hodgkin Lymphoma – Pipeline by Xenetic Biosciences (UK) Ltd, H2 2016 329

Non-Hodgkin Lymphoma – Pipeline by ZIOPHARM Oncology Inc, H2 2016 330

Non-Hodgkin Lymphoma – Pipeline by Zymeworks Inc, H2 2016 331

Assessment by Monotherapy Products, H2 2016 332

Assessment by Combination Products, H2 2016 333

Number of Products by Stage and Target, H2 2016 335

Number of Products by Stage and Mechanism of Action, H2 2016 366

Number of Products by Stage and Route of Administration, H2 2016 396

Number of Products by Stage and Molecule Type, H2 2016 398

Non-Hodgkin Lymphoma – Dormant Projects, H2 2016 1573

Non-Hodgkin Lymphoma – Dormant Projects (Contd..1), H2 2016 1574

Non-Hodgkin Lymphoma – Dormant Projects (Contd..2), H2 2016 1575

Non-Hodgkin Lymphoma – Dormant Projects (Contd..3), H2 2016 1576

Non-Hodgkin Lymphoma – Dormant Projects (Contd..4), H2 2016 1577

Non-Hodgkin Lymphoma – Dormant Projects (Contd..5), H2 2016 1578

Non-Hodgkin Lymphoma – Dormant Projects (Contd..6), H2 2016 1579

Non-Hodgkin Lymphoma – Dormant Projects (Contd..7), H2 2016 1580

Non-Hodgkin Lymphoma – Dormant Projects (Contd..8), H2 2016 1581

Non-Hodgkin Lymphoma – Dormant Projects (Contd..9), H2 2016 1582

Non-Hodgkin Lymphoma – Dormant Projects (Contd..10), H2 2016 1583

Non-Hodgkin Lymphoma – Dormant Projects (Contd..11), H2 2016 1584

Non-Hodgkin Lymphoma – Dormant Projects (Contd..12), H2 2016 1585

Non-Hodgkin Lymphoma – Dormant Projects (Contd..13), H2 2016 1586

Non-Hodgkin Lymphoma – Dormant Projects (Contd..14), H2 2016 1587

Non-Hodgkin Lymphoma – Dormant Projects (Contd..15), H2 2016 1588

Non-Hodgkin Lymphoma – Dormant Projects (Contd..16), H2 2016 1589

Non-Hodgkin Lymphoma – Dormant Projects (Contd..17), H2 2016 1590

Non-Hodgkin Lymphoma – Dormant Projects (Contd..18), H2 2016 1591

Non-Hodgkin Lymphoma – Dormant Projects (Contd..19), H2 2016 1592

Non-Hodgkin Lymphoma – Dormant Projects (Contd..20), H2 2016 1593

Non-Hodgkin Lymphoma – Dormant Projects (Contd..21), H2 2016 1594

Non-Hodgkin Lymphoma – Dormant Projects (Contd..22), H2 2016 1595

Non-Hodgkin Lymphoma – Dormant Projects (Contd..23), H2 2016 1596

Non-Hodgkin Lymphoma – Dormant Projects (Contd..24), H2 2016 1597

Non-Hodgkin Lymphoma – Dormant Projects (Contd..25), H2 2016 1598

Non-Hodgkin Lymphoma – Dormant Projects (Contd..26), H2 2016 1599

Non-Hodgkin Lymphoma – Dormant Projects (Contd..27), H2 2016 1600

Non-Hodgkin Lymphoma – Dormant Projects (Contd..28), H2 2016 1601

Non-Hodgkin Lymphoma – Dormant Projects (Contd..29), H2 2016 1602

Non-Hodgkin Lymphoma – Dormant Projects (Contd..30), H2 2016 1603

Non-Hodgkin Lymphoma – Dormant Projects (Contd..31), H2 2016 1604

Non-Hodgkin Lymphoma – Dormant Projects (Contd..32), H2 2016 1605

Non-Hodgkin Lymphoma – Discontinued Products, H2 2016 1606

Non-Hodgkin Lymphoma – Discontinued Products (Contd..1), H2 2016 1607

Non-Hodgkin Lymphoma – Discontinued Products (Contd..2), H2 2016 1608

Non-Hodgkin Lymphoma – Discontinued Products (Contd..3), H2 2016 1609

Non-Hodgkin Lymphoma – Discontinued Products (Contd..4), H2 2016 1610

Non-Hodgkin Lymphoma – Discontinued Products (Contd..5), H2 2016 1611

Non-Hodgkin Lymphoma – Discontinued Products (Contd..6), H2 2016 1612

Non-Hodgkin Lymphoma – Discontinued Products (Contd..7), H2 2016 1613

Non-Hodgkin Lymphoma – Discontinued Products (Contd..8), H2 2016 1614

Non-Hodgkin Lymphoma – Discontinued Products (Contd..9), H2 2016 1615

Non-Hodgkin Lymphoma – Discontinued Products (Contd..10), H2 2016 1616

Non-Hodgkin Lymphoma – Discontinued Products (Contd..11), H2 2016 1617

Non-Hodgkin Lymphoma – Discontinued Products (Contd..12), H2 2016 161

List of Figures

List of Figures

Number of Products under Development for Non-Hodgkin Lymphoma, H2 2016 58

Number of Products under Development for Non-Hodgkin Lymphoma – Comparative Analysis, H2 2016 59

Number of Products under Development by Companies, H2 2016 60

Number of Products under Investigation by Universities/Institutes, H2 2016 77

Comparative Analysis by Late Stage Development, H2 2016 79

Comparative Analysis by Clinical Stage Development, H2 2016 80

Comparative Analysis by Early Stage Products, H2 2016 81

Assessment by Monotherapy Products, H2 2016 332

Assessment by Combination Products, H2 2016 333

Number of Products by Top 10 Targets, H2 2016 334

Number of Products by Stage and Top 10 Targets, H2 2016 334

Number of Products by Top 10 Mechanism of Actions, H2 2016 365

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 365

Number of Products by Top 10 Routes of Administration, H2 2016 395

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 395

Number of Products by Top 10 Molecule Types, H2 2016 397

Number of Products by Stage and Top 10 Molecule Types, H2 2016 397

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports